Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of BI 836880 alone and with BI 754091 in Japanese patients with advanced solid tumours
jRCT2080224681Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 836880 and ezabenlimab in Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Started May 2019; status: completed.
02
Drugs
BI 836880ezabenlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224681.